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Abstract
Introduction We have previously shown that a subpopula-
tion of naturally occurring human IgGs has therapeutic
potential for the amyloid-associated disorders. These
molecules cross-react with conformational epitopes on
amyloidogenic assemblies, including amyloid beta (Aβ)
protein fibrils that are a pathological hallmark of
Alzheimer’s disease.
Materials and Methods Using our europium-linked immu-
nosorbant assay, we established that ∼95% of 260 screened
donor plasma samples had amyloid fibril-reactive IgGs and
Aβ conformer-reactive IgGs with minimal binding to Aβ
monomers. Anti-amyloidogenic reactivity was diverse and
attributed to Aβ targeting multiple fibril-related binding
sites and/or variations in multidentate binding.
Results and Discussion There was no correlation between
anti-fibril and anti-oligomer reactivity and donor age (19 to
60 years old) or gender. These findings demonstrate the
inherent but diverse anti-amyloidogenic activity of natural
IgGs contained in normal plasma.
Conclusion Our studies provide support for investigating
the clinical significance and physiological function of this
novel class of antibodies.
Keywords Natural.IgGs.amyloid.Aβ.IVIG
Introduction
ApathologicalhallmarkofAlzheimer’sdisease(AD)andmore
than 25 other incurable protein misfolding diseases, called the
amyloidoses, is the extracellular deposition of amyloid fibrils
from unrelated proteins or peptides [1]. The primary culprits
for AD are prefibrillar amyloidogenic assemblies of amyloid
beta (Aβ), a proteolyzed transmembrane 39–43 fragment of
amyloid precursor protein [2–4]. However, fibril deposition
may be the primary toxic event for several non-AD
amyloidoses, including primary AL amyloidosis [5].
Currently, immunotherapy directed against amyloidogenic
protein is the primary therapeutic approach for AD and is a
recent strategy for other amyloid-associated disorders [6].
Active vaccination with Aβ or passive administration of
anti-Aβ antibodies has shown promise in AD animal models
and in some AD patients by inducing neuritic plaque
clearance, neutralizing neurotoxic Aβ oligomers, and/or
improving cognitive functioning [7–9]. Antibodies that
specifically react with pathogenic amyloidogenic aggregates
that do not bind to the normally secreted precursor protein
are less likely to have adverse effects. Presumably, such
natural IgG antibodies contained in intravenous immuno-
globulin (IVIG) are at least partly responsible for its
promising clinical effects [10, 11]. We have recently shown
that these antibodies cross-react with conformational
epitopes on amyloid fibrils and oligomers, including binding
to cross-linked β-amyloid protein species (CAPS) [12].
These antibodies also inhibit in vitro amyloid fibril growth
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mice [12, 13]. The results of our studies on a large number of
plasma donor specimens provide new information on the
extent and specificity of natural anti-amyloidogenic
conformer-reactive IgGs, which are contained in presumably
healthy individuals.
Methods
Peptides, Proteins, and Antibodies Human 40- and 42-mer
Aβ peptides were purchased from Quality Controlled
Biochemicals (Hopkinton, MA, USA); mass spectrometric
analysis showed them to be >90% pure. Before using, the
lyophilized Aβ40 peptide was disaggregated by sequential
exposure to trifluoroacetic acid, hexafluoroisopropanol
(HFIP; Pierce, Rockford, IL, USA), and 2 mM NaOH,
followed by 2× PBS (1× final). The ultracentrifuged sample
yielded a final peptide concentration of ∼0.2 mg/mL [12].
The soluble 42-mer peptide was prepared at ∼0.04 mg/mL
in PBS by pretreatment with HFIP/NaOH [12]. The peptide
concentrations were determined at A215 nm by reverse-phase
HPLC using an Aβ 40 standard curve or by the MicroBCA
assay (Pierce).
Recombinant immunoglobulin light chain (LC) λ6
variable domain, Jto, was produced in an Escherichia coli
expression system and purified using Amberlite XAD-7
(Sigma-Aldrich, St. Louis, MO, USA) [13]. The soluble LC
was sterile-filtered using a 0.22-µm polyvinylidene fluoride
25-mm Millex-GV syringe-driven filter unit (Millipore,
Bedford, MA, USA). SDS-PAGE analyses confirmed that
the protein was >90% pure, and protein concentration was
determined by the MicroBCA assay.
Normal donor plasma, coagulation reference plasma,
which consisted of pooled plasma from healthy donors
aged 20 to 60, and IVIG (Gammagard liquid) were
provided by Baxter BioScience (Vienna, Austria). The
blocking agent, essentially fatty-acid-free bovine serum
albumin, was purchased from Sigma. All other reagents
were of analytical grade.
Preparation of Peptide and Protein Aggregates Soluble
CAPS was prepared from the synthetic 40- or 42-mer Aβ
peptides by incubation with 1.1 µM horseradish peroxidase
and 250 µM H2O2 in PBS at 37°C for 3 h, and then purified
using copper (CuSO4) precipitation [12]. CAPS was
quantified using SDS PAGE (4–12% Bis Tris precast gels;
Invitrogen, Carlsbad, CA, USA) and the MicroBCA assay.
Electrospray ionization mass spectrometry (Applied Biosys-
tems, Foster City, CA, USA) and dityrosine fluorescence
(excitation at 320 nm and emission between 350 and 550 nm)
confirmed that the aggregates consisted of low molecular
weight (<38 kDa), cross-linked SDS stable species.
Aβ40 and LC fibrils were grown from the soluble
precursor proteins in PBS containing 0.02% sodium azide
(PBSA). The reaction was monitored by thioflavin T
fluorescence [13]. Fibrils were harvested by centrifugation
at 20,200×g for 30 min at room temperature, then sonicated
(2×30-s bursts) with a probe sonicator disruptor (Teledyne
Tekmar, Mason, OH, USA), aliquoted, and stored at −20°C.
IgG Purification IgGs from donor plasma pools were
isolated using a Melon Gel IgG Spin Purification Kit
(Pierce). SDS-PAGE confirmed that the resultant samples
were >95% pure. Antibody concentration was determined
by absorbance at A280 nm with the use of a molar extinction
coefficient of 210,000 M
−1 cm
−1.
Antibody Binding Assay Antibody reactivity with amyloid
fibrils, CAPS, and monomeric Aβ40 was determined at 37°
C using the plate-immobilized conformers in our europium-
linked immunosorbant assay (EuLISA) [13]. All measure-
ments were done in triplicate (error bars in the figures
represent SD), and antibody concentrations that gave half-
maximal binding (EC50 values) were determined from the
sigmoidally fit binding curves (SigmaPlot 2000 ver. 6;
Systat Software, Chicago, IL, USA).
TheEuLISAwasperformedwitha1:20orserialdilutionof
plasma or purified IgGs in assay buffer (1% BSA in PBSA
containing 0.05% Tween 20) in activated high-binding
microtiter plate wells (COSTAR, Corning, NY, USA) coated
with 400 ng of target protein and blocked with 1% BSA
(Sigma-Aldrich) in PBSA. A biotinylated goat anti-human
IgG (γ-chain specific, Sigma-Aldrich) served as the second-
ary antibody. After the addition of a Eu
3+ streptavidin
conjugate, followed by the releasing enhancement solution,
Eu
3+ time-resolved fluorescence was measured using a
Victor
2 1420 Multilabel Counter (Perkin Elmer, Waltham,
M A ,U S A ) .T h ea m o u n t( f M )o fl a n t h a n i d er e l e a s e dw a s
calculated from a standard curve using known concentrations
of Eu
3+.
To establish whether antibody binding was affected by a
putative inhibitory plasma molecule, binding studies were
doneafterpretreating thepreparationwithacid(0.1M glycine
HCl, pH 3.5), followed by dialysis against PBS (Amicon
Ultra-4 filter unit, 30,000 Da m.w. cutoff, from Millipore) to
dissociate antigen–antibody complexes [14]. Assay signal
was normalized for high-throughput plasma screening using
a standard curve on each plate of coagulation reference
plasma against the plate-immobilized amyloidogenic con-
former.
Assurances Studies involving human specimens were in
accordance with a protocol approved by the University of
Tennessee Graduate School of Medicine’s Institutional
Review Board.
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Anti-amyloidogenic Activity of Natural IgGs Contained in
Normal Plasma The construction of full antibody binding
curves and a high-throughput screen of 260 plasma estab-
lishedthe inherentanti-amyloidogenicconformerreactivityof
natural IgGs contained in normal human plasma (Figs. 1 and
2). These molecules were detected in essentially all (∼95%)
plasma. Surprisingly, the avidity of IgG binding to aggre-
gated amyloidogenic conformers for each sample was
similar, with EC50 values of ∼100–800 nM. The relatively
large EC50 values reflected the small fraction, ∼0.2% of
polyclonal IgGs in normal plasma that target Aβ [12, 13].
Diverse maximum binding signal amplitudes were obtained
for individual and pooled plasma. These differences were not
due to a putative inhibitory plasma molecule, such as
endogenous Aβ, that interfered with antibody binding [14].
The binding curve for an equimolar mix of high- and low-
reactive plasma pools against Aβ fibrils or CAPS was
essentially the same as that for the high-reactive preparations
(Figs. 1d and 2d).
Similar with IVIG, natural antibodies contained in normal
plasma had comparable reactivity with Aβ fibrils and CAPS
(generated from the 40- and 42-mer Aβ peptides), but
relatively weak interactions with the monomeric peptide
(Figs. 1 and 2)[ 12]. This indicated that natural anti-
amyloidogenic conformer IgGs display the same amyloid
fibril and oligomer cross-reactivity, whether in plasma or as
purified molecules [12]. These molecules also bound with
similarly avidity to LC fibrils, with EC50 value of ∼100–
300 nM that was consistent with reactivity against confor-
mational epitopes that are less reliant on the amyloidogenic
protein’s primary sequence (Fig. 2)[ 13]. Nevertheless, the
mean value for plasma IgG reactivity against Aβ fibrils, 24±
19 Eu
3+ fmoles, was ∼2-fold greater than that against LC
fibrils, 13.4±13 Eu
3+ fmoles (P<0.0001, paired t test). This
indicated that although amyloidogenic conformers have
common epitopes, their density can vary.
Our plasma screening results were confirmed by ∼5-fold
larger maximum signal amplitude for binding curves for
amyloid conformer-reactive IgGs from a pool of 20 plasma
that were identified as “high” reactive samples compared
with a mixture of “low” binders (Fig. 2b, c). The relatively
small signal for the low-reactive plasma pool was not due
to a proportion of antibody that was bound to naturally
occurring amyloidogenic antigens since similar binding
curves were obtained for the purified IgGs, with or without
acid pretreatment to dissociate putative antibody–antigen
complexes (14; Figs. 2d, e).
Age- and Gender-Related Anti-amyloidogenic Conformer
Reactivity There was no significant correlation between anti-
Aβ fibril and anti-CAPS reactivity with donor age (∼19 to
∼60 years old; P=0.238 and 0.859 for fibril and CAPS
reactivity, respectively; nonparametric Kruskal–Wallis test)
or gender (P=0.161 and 0.058 for fibril and CAPS reactivity,
respectively; nonparametric two-tailed Mann–Whitney t test;
Fig. 3).
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Fig. 1 Aβ40 conformer binding by IgGs contained in normal plasma.
Representative antibody binding curves for normal plasma IgGs (filled
circle, unfilled circle, unfilled square, filled triangle, unfilled triangle)
against Aβ fibrils (a), CAPS (b), and Aβ monomers (c). d Binding
curves for high (filled circle) and low (unfilled circle) reactive plasma
pools, and for an equimolar mix (unfilled triangle) against Aβ fibrils.
Each plasma pool consisted of 15 plasma specimens. CAPS indicates
dityrosine cross-linked β-amyloid protein species
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Given the urgent need for novel therapeutics and diagnostics
for amyloid-associated disorders, it is vital that we advance
current limited understanding about the prevalence, clinical
significance,andphysiologicalfunctionofnaturallyoccurring
anti-amyloidogenic conformer IgGs. Our findings demon-
strate that these antibodies are inherently present in normal
plasma, independent of donor age (∼19–60 years old) or
gender. The unique manner in which these IgGs bind to
amyloid fibrils and oligomers is evident from their ability to
maintain reactivity in the presence of endogenous plasma
molecules, several of which bind to Aβ [15]. Notably, these
antibodies are also present in the plasma of children and
naïve mice (B. O’Nuallain, A. Solomon, unpublished data,
2009) [16]. This suggests that they may be part of the innate
immune response for clearing endogenous/exogenous “mis-
folded proteins” by binding to amyloid fibril-like epitopes.
Previous studies have differed on the prevalence and age-
and gender-related amyloidogenic conformer reactivity of
natural plasma IgGs. [16–18]. These discrepancies presum-
ably reflected the limits of detection by the different assays.
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Fig. 2 EuLISA screen of LC fibril and Aβ conformer binding by
IgGs contained in 260 donor plasma samples. a Comparison of
amyloidogenic conformer IgG binding using a 1:20 dilution of
plasma. Solid lines represent the median values, which with the
exception of the median value for binding to LC fibrils compared with
that for CAPS, significantly differed (P<0.0001 in a nonparametric
Kruskal–Wallis test). To eliminate plate-to-plate variability, assay
signals were normalized using a standard curve constructed from
coagulation reference plasma. b–c Antibody binding curves for high
(filled circle) and low (unfilled circle) reactive plasma pools and for an
equimolar mix (unfilled triangle) against Aβ fibrils (b), and CAPS
generated from the 40-mer Aβ peptide (c). Similar binding curves to
those shown in (b) and (c) were also determined for the latter plasma
pools against LC fibrils and CAPS generated from Aβ42 (data not
shown). Each plasma pool consisted of 20 plasma specimens. d
Binding curves for purified plasma IgGs from the high (filled circle)
and low (filled triangle) reactive plasma pools against LC fibrils
compared with curves generated using the respective plasma (unfilled
circle, unfilled triangle). e Antibody binding curves for essentially the
same reagents described in (d), but each antibody sample was
pretreated with acid and dialysis (m.w. cutoff of 30,000 Da), and
then neutralized to remove any putative inhibitor of antibody–
amyloidogenic conformer interactions. CAPS indicates dityrosine
cross-linked β-amyloid protein species, LC human Ig light chain
S40 J Clin Immunol (2010) 30 (Suppl 1):S37–S42In some cases, these detection abilities were reduced when
screening against disaggregated soluble Aβ with which
natural antibodies are only weakly reactive as a result of a
surface-induced amyloid-like epitope [12]( F i g s .1 and 2).
These discrepancies were unlikely due to screening plasma
against different aggregated Aβ conformers, because we
have shown that natural IgGs cross-react with common
conformational epitopes on all amyloid fibrils or oligomers
tested [12, 13]. Although the current study showed no
correlation between the age or gender of plasma donors and
anti-amyloidogenic activity, it is possible that an association
exists beyond the donor population age range of 19 to
60 years old [17, 18]. However, screening normal plasma
from presumably healthy elderly individuals older than
60 years is problematic because these samples are likely to
contain an additional population of amyloid-reactive anti-
bodies that are not naturally occurring but generated against
pathologic Aβ assemblies, which may be present decades
before AD is diagnosed.
The molecular basis for natural antibody–amyloidogenic
conformer interactions has not been well defined. The
epitopes involved are not exposed on native proteins and
presumably contain unique higher-ordered structure and/or
novel clusters of amino acids. Given that these IgGs react
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Fig. 3 Donor age- and gender-related anti-amyloidogenic IgG
activity. a–b The plots show donor age versus plasma IgG reactivity
against Aβ40 fibrils (a) and CAPS (b). Each solid line represents the
median value. The plots show that there was no significant correlation
with donor age (P=0.238 and 0.859 for fibril and CAPS reactivity,
respectively; nonparametric Kruskal–Wallis test). Data were obtained
from a bulk screen of 260 normal plasma specimens as shown in
Fig. 2. c–d The plots show normal donor gender versus plasma IgG
reactivity against Aβ fibrils (c) and CAPS (d). Each solid line
represents the median value. The plots show that there was no
significant correlation with donor gender (P=0.161 and 0.058 for
fibril and CAPS reactivity, respectively; nonparametric two-tailed
Mann–Whitney t test). The data were obtained from a screen of 260
normal plasma specimens as shown in Fig. 2. CAPS indicates
dityrosine cross-linked β-amyloid protein species
J Clin Immunol (2010) 30 (Suppl 1):S37–S42 S41with conformational epitopes on “misfolded” protein
aggregates, their binding may not involve complementary
determining regions that are typically involved in antibody–
antigen interactions. Preliminary studies using antibody
fragments [F(ab’) and F(ab’)2] indicate that the Fc portion
and/or hinge region are critical for natural human IgG
binding to aggregated Aβ (B. O’Nuallain, A. Solomon,
unpublished data, 2009). Such interactions may involve a
complementary surface that is exposed on a partially
unfolded antibody or a superantigen-like binding by the
native protein. Nevertheless, antibody reactivity is not due
to insoluble antibody aggregates because the same IgG
reactivity with Aβ fibrils was obtained whether plasma was
centrifuged or untreated.
The similar EC50 values that were obtained for high- and
low-reactive plasmas are intriguing and indicate that each
sample contained a subpopulation of natural IgGs that had
comparable avidity for amyloidogenic conformers (Figs. 1
and 2). However, these specimens had diverse maximum
binding signal amplitudes, which indicate that each antibody
subpopulation differed in its ability to bind to a variety of
fibril-related conformational epitopes. Alternatively, this may
have reflected the different propensities of the antibody
subpopulations for multidentate binding to the same structural
repeats.
Conclusions
We have established that natural IgGs contained in normal
plasma produce inherent, but diverse, anti-amyloidogenic
activity. Thus, the beneficial effect of IVIG in some AD
patients [10, 11] may have been due to the enriched diversity
of each patient’sA β-reactive IgG pool. This diversity could
have improved cognition [10, 11] by the enhancement of
neuritic plaque clearance [13, 19], inhibition of fibril growth
[13, 20], neutralization of neurotoxic Aβ oligomers [20], and
reduction of Aβ brain pool. Taken together, our studies
support future investigations of the clinical significance and
physiological function of naturally occurring amyloidogenic
conformer-reactive antibodies.
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